

# Update from the TYA SSCRG analytical work programme



#### Summary

- Highlights from current work programme
- Next year's work programme
- "Augmented registration system"



#### Highlights from current work programme

- Trends in survival for TYA with cancer in the UK
- International comparisons of TYA cancer mortality rates
- Radiotherapy use among TYA cancer patients in England
- Access to specialist care



#### Trends in survival for TYA with cancer in the UK

- Five-year relative survival
- 15-24 year olds
- 1992-1996, 1997-2001, 2002-2006
- 18 types of cancer




#### Five-year survival for all cancers combined

Voor	Males		Females		Persons	
Year	%	P value*	%	P value*	%	P value*
1992-1996	73.5	-	78.2	-	75.7	-
1997-2001	77.0	<0.001	80.6	0.005	78.6	<0.001
2002-2006	80.6	<0.001	83.9	<0.001	82.2	<0.001

<sup>\*</sup>compared with 1992-1996




## Five-year survival for 1992-1996 and 2002-2006 by cancer type






## Five-year survival for 1992-1996 and 2002-2006 by cancer type





## Five-year survival for 1992-1996 and 2002-2006 by cancer type





#### Results from USA\*

- SEER
- Diagnosed during 2000-2007
- Five –year survival
- 15-39 year olds

\*A Bleyer JAYAO 2011: 37-41



#### UK vs US

- 16 types of cancer
- Within 5% for 9
- UK higher: ALL, AML, CNS, cervical cancer
- US higher: osteosarcoma (11.8%), Ewing sarcoma (5.6%)



#### Osteosarcoma

- Small non-significant improvement in survival (3.4%)
- Lower survival than in US
- Lower survival than 0-14 and 25-49 year olds in UK (all bone)\*

\*Survival in teenagers and young adults with cancer in the UK. C O'Hara, A Moran. 2012 NCIN



#### Soft tissue sarcoma (STS)

- Survival 11% lower in males (not including Rhabdo)
- Lower survival than in 0-14 and 25-49 in UK (all STS)



#### International comparisons of TYA cancer mortality rates

- Mortality rates available for almost all countries
- Mortality determined by incidence and survival
- WHO mortality database



## Age-specific mortality rates per 100,000 population for all cancers combined for 2006-2010 for males

Rank Order	15-19		20-24		15-24	
1	Nordic	3.3	Australia	4.2	Australia	3.9
2	Canada	3.4	Germany	4.6	Nordic	4.1
3	Australia	3.5	Nordic	4.9	Germany	4.1
4	Germany	3.6	Canada	5.1	Canada	4.3
5	USA	3.6	UK	5.2 (5*)	Netherlands	4.5
6	Netherlands	3.6	Spain	5.2	USA	4.6
7	France	4.1	Netherlands	5.4	UK	4.7 (5*)
8	UK	4.3 (5*)	USA	5.7	France	5.1
9	Italy	5.2	France	6.2	Spain	5.5
10	Spain	5.8	Italy	6.6	Italy	5.9

<sup>\*</sup>Rank order of UK for all cause mortality rates



## Age-specific mortality rates per 100,000 population for all cancers combined for 2006-2010 for females

Rank Order	15-19		20-24		15-24	
1	Canada	2.4	Germany	3.1	Germany	2.9
2	Germany	2.6	Canada	3.3	Canada	2.9
3	USA	2.6	Nordic	3.3	France	3.1
4	France	2.7	Netherlands	3.5	Netherlands	3.1
5	Netherlands	2.7	France	3.5	USA	3.1
6	UK	3.0 (7*)	Australia	3.7	Nordic	3.2
7	Nordic	3.1	USA	3.7	UK	3.4 (6*)
8	Australia	3.1	UK	3.8 (6*)	Australia	3.4
9	Spain	3.4	Spain	4.0	Spain	3.7
10	Italy	4.1	Italy	4.4	Italy	4.3

<sup>\*</sup>Rank order of UK for all cause mortality rates



#### Further work

- Comparisons for CNS, NHL, lymphoid leukaemia and bone
- Years of lives gained if cancer death rates in UK same as other countries



#### Use of radiotherapy in TYA

- Variation in use of XRT by diagnosis, age, gender and region
- More detailed analysis led by Matt Williams



#### Methods

 Record-match national radiotherapy dataset (RTDS) against the national cancer data repository (NCDR)



#### Access to specialist care

- "Notification of TYA with cancer to a PTC centre 2009-2010"
- Report published on the NCIN website in April 2013




#### Methods

- PTCs send us form on all TYA patients notified to their TYA MDT
- Called the TYAC notification system
- Record-matched against NCDR
- Calculate % notified by diagnosis, age, gender and region
- Use HES and cancer waits to determine trust of treatment




### Percentage of patients diagnosed in 2009-2010 who were notified by age group and diagnosis






### Percentage of patients diagnosed in 2009-2010 who were notified by age group and government office region (GOR) of residence



Error bars represent 95% confidence intervals



### Number of patients aged 15 to 24 years diagnosed in 2009-2010 who were treated at each PTC and not notified



<sup>\*</sup> includes Alder hey and The Royal Liverpool Hospital patients

†University of Leicester and Nottingham University Hospitals act together as the Teenage and Young Adult East Midlands Integrated Cancer Service




#### Next year's work programme

- Deaths within a year of diagnosis
- Survival by whether notified to a TYA MDT
- Variations in % of patients notified to a TYA MDT in 2009-2011



### 30 day and one year percentage mortality for individuals aged 15-24 diagnosed in England in 2005-2009 by diagnostic group\*



<sup>30</sup> day mortality 1 year mortality

<sup>\*</sup>Pattern of deaths in the year following diagnosis in cancer patients aged 15-24 years in England. Tony Moran, Debasree Purkayastha, Catherine O'Hara. NCIN 2013



## Deaths in first year in ALL in those diagnosed in 2005-2009

Number of cases	Number of deaths	% of deaths
353	51	14.4%



#### Record-match NCDR and UKALL2003 datasets

- % participating in trial
- One-year survival in those in and not in the trial
- Differences in pattern of deaths in first year
- Keeping the Haematology CRG informed



#### Possible further work

- Classifying deaths into due to (a) disease (b) complications of treatment
- Relate outcomes to where and how managed?
- Small numbers and political sensitivities



#### Survival by whether notified to a TYA MDT

- Compare one-year survival in those with and without a TYAC form
- Exploratory



#### TYAC notification system

- Receive a form for 62% of 15-18 year olds and 34% of 19-24
- All data items on form are on COSD



#### Usefulness

- Form received: indicator of access to specialist care
- Data on form
- Not used for routine statistics



#### Way forward

- Check if COSD data of sufficient quality to stop
- Meantime?
- Devolved nations



#### Our team

Sabrina Sandhu

Maria Khan

Debasree Purkayastha

Busani Ndlela